# Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer

Source: https://onco.cc/trials/nct05709249/  
OnCo record `nct05709249` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of XLJDOD compound granule in colorectal cancer, run by Jiangsu Famous Medical Technology Co., Ltd., now recruiting.

## Summary

Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer is a phase 3 interventional study registered as NCT05709249 by Jiangsu Famous Medical Technology Co., Ltd., with 730 participants planned, started 2022-12-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: XLJDOD compound granule and placebo (XLJDOD mimetic agent).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05709249
- Phase: 3
- Setting: Efficacy of Xian-Lian-Jie-Du Optimization Decoction As an Adjuvant Treatment for Prevention of Recurrence of Stage IIIB/IIIC Colon Cancer：a Study Protocol for a Randomized Controlled Trial
- Sponsor: Jiangsu Famous Medical Technology Co., Ltd.
- Enrolled: 730

## Sources

- ClinicalTrials.gov NCT05709249: https://clinicaltrials.gov/study/NCT05709249

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct05709249.json